Semaglutide Drops for Weight Loss: Do They Exist?

Are semaglutide weight loss drops a real, licensed product?

They are not. Searching for weight loss drops semaglutide turns up a busy market of compounded liquids, sublingual tinctures and vials sold through social media and grey-market websites, none of which holds MHRA authorisation for weight management. In the UK, a medicine can only be marketed for a specific condition once it has passed the regulator's rigorous assessment of quality, safety and efficacy. Semaglutide has passed that process twice for weight loss, but the resulting licensed products are a subcutaneous injection and a tablet, not a liquid.

Compounded preparations occupy a legal grey area. A pharmacist may prepare an unlicensed medicine to meet a specific patient's need when no licensed alternative is suitable, but that narrow clinical exception does not extend to manufacturing and selling drops at scale to the general public. The MHRA has been explicit: large seizures of fake and unlicensed GLP-1 pens and preparations have been made across the UK, and some counterfeit products have contained substances dangerous to people who are not diabetic. If a seller is offering semaglutide in any form without asking you for a prescription, that is a clear warning sign worth taking seriously. You can report suspicious sellers directly through the MHRA's Yellow Card scheme.

The short answer: semaglutide drops are not a product your GP, specialist or legitimate online pharmacy can prescribe, because no such licensed product exists.

What licensed semaglutide for weight loss does look like

The licensed UK options are worth knowing in some detail, because they are quite different from each other. Wegovy, made by Novo Nordisk, is a once-weekly subcutaneous injection delivered via a pre-filled pen. The dose starts low and is increased gradually by a prescriber, the titration schedule is there to help your body adjust and to keep side effects manageable. The NHS semaglutide medicines page gives a clear overview of both how it works and what to expect.

Then there is the oral route. On 11 June 2026 the MHRA approved Wegovy tablets, making the UK the first country in Europe to licence an oral GLP-1 medicine for weight management. The tablet is taken once daily, first thing in the morning on an empty stomach, with a small amount of plain water, at least thirty minutes before food or any other medicine. It follows its own dose escalation from 1.5mg up to a 25mg maintenance dose. No refrigeration is needed, which makes it considerably more practical for travel or anyone who finds injections difficult.

The STEP 1 trial, published in the New England Journal of Medicine, found that participants using the 2.4mg weekly injection lost around 15% of their body weight on average over 68 weeks alongside lifestyle changes. The oral tablet programme (OASIS 4) showed approximately 13.6% average weight loss over 64 weeks. For more on how the mechanism actually produces these results, the explanation of how semaglutide works covers the GLP-1 pathway in plain terms.

None of this is available as a drop. Worth knowing.

Why do unlicensed semaglutide drops keep appearing online?

Partly because GLP-1 medicines have received intense public attention, partly because demand outstripped supply for a period, and partly because the margins on unlicensed preparations can be significant. Compounding pharmacies in some other countries have produced injectable and oral semaglutide preparations that then travel across borders, sometimes rebranded as drops or sprays to sidestep customs checks.

The risk is real and specific. Semaglutide is a peptide, it is sensitive to temperature, pH and handling in ways that a person buying a vial online cannot verify. Dosing accuracy in a liquid drop format, with no validated delivery mechanism, is essentially unknown. People have been hospitalised after using counterfeit GLP-1 preparations containing undisclosed insulin, and the MHRA's enforcement operations have seized what amounts to millions of unlicensed doses from UK addresses. The semaglutide overview has more context on the licensed medicine itself, which is the reference point for understanding just how far these unlicensed versions fall short.

If something is being sold cheaply, without a clinical assessment, with no GPhC-registered pharmacy behind it, and in a format that does not match any licensed product, those facts, taken together, should give you pause. A discount on a product that may not contain what it claims to is not a bargain.

What is the right route if you want semaglutide for weight management?

A private prescription, following an assessment with a GPhC-registered prescriber, is the legal and safe path if you do not meet NHS criteria or prefer not to wait. Wegovy on the NHS is available through specialist weight management services under NICE's guidance (TA875), though waiting lists are often long and eligibility criteria are specific. For context on what private treatment typically costs and what to look for in a provider, the Wegovy pricing page sets out the honest picture without inflating expectations.

When you do go through a legitimate provider, what actually arrives is straightforward: a tracked DPD delivery, plain unbranded packaging, and inside it a pre-filled Wegovy pen. No mystery ingredients. No unlabelled vial. Just the medicine your prescriber approved, in the format the MHRA licensed, at the dose your clinical assessment determined was right for you.

For a fuller look at the Wegovy injection itself, including eligibility and what to expect from treatment, the Wegovy treatment page is the place to start. You can also explore the broader picture of semaglutide and weight loss, or read about how semaglutide is used for weight loss in practice. If you think you might be eligible and want to speak to a prescriber, check your eligibility with our clinical team.